Tractor Supply Co (TSCO) Healthy Sales Growth, Cytori Therapeutics (CYTX) FDA Oks Continuation of ATHENA Trial Enrollment |
Posted: October 23, 2014 |
Crown Equity Holdings Inc. (CRWE) CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. CRWE is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of website communities. The CRWE Network has reached the 1440th community website in the U.S., associated with 3320 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada. CRWE has included the City of Niagara Falls, NY ( www.niagarafalls.ny.crwe-pr.com ) to the CRWE Network. Currently, the city's main industry is tourism. Niagara Falls is visited by almost ten million people each year and is considered one of the United States' top ten tourist destinations With an estimated population in 2013 (U.S. Census Bureau) of approximately 49,468, Niagara Falls, NY represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally CRWE and PolarWeb Media, LLC reported a Joint Venture agreement to engage in increasing web traffic to selected websites. CRWE will receive 50% of the revenues generated by PolarWeb Media through the use of the CRWE Network, with PolarWeb Media having the remaining 50%. PolarWeb Media, LLC will focus on driving traffic and generating ad revenues. Online video is quickly becoming one of the most popular forms of content on the Internet. Globally, according to Cisco Visual Networking Index, IP video traffic will be 79% of all consumer Internet traffic in 2018. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** Tractor Supply Company (TSCO) Keep a close eye on TSCO. It reported strong increases in sales, operating margin and earnings on its financial results, and the company is raising its full year fiscal 2014 sales and earnings per share outlook to the high end of the previously provided ranges of $5.62 billion to $5.70 billion in net sales, 2.5% to 4.0% in comparable store sales and $2.54 to $2.62 in diluted earnings per share. For the third quarter 2014, TSCO posted net sales of $1.36 billion, a 12.6% increase year over year, gross profit of $464.1 million, an 11.6% increase compared to the same period the prior year, and net income of $76.6 million, or $0.55 per diluted share, versus net income of $64.8 million, or $0.46 per diluted share in the third quarter 2013. TSCO is the largest rural lifestyle retail store chain in the United States. TSCO's stores are focused on supplying the lifestyle needs of recreational farmers and ranchers and others who enjoy the rural lifestyle, as well as tradesmen and small businesses. Stores are located primarily in towns outlying major metropolitan markets and in rural communities. More about Tractor Supply Company (TSCO) at www.TractorSupply.com ** Cytori Therapeutics, Inc. (CYTX) Cardiovascular disease is the number one cause of death in the U.S., Europe, and the majority of other countries around the world. Advanced heart disease also accounts for many disabilities, lost productivity, and diminished lifestyle. CYTX performed preclinical (in the laboratory) studies that suggested a restoration of heart function following the application of Adipose-Derived Regenerative Cells (ADRCs). ATHENA is a multi-center, prospective, randomized, double-blind safety and feasibility trial to investigate the use of Cytori Cell Therapy in patients with heart failure due to ischemic heart disease. CYTX has received notification from the FDA that the company has provided additional information sufficient to support continuation of enrollment in its ATHENA cardiovascular trials. The FDA has agreed that the submitted data and protocol amendments support the fact that there are no subject protection concerns that preclude continuation of the trials. The ATHENA trials have enrolled a total of 31 patients thus far but enrollment was stopped last May by CYTX based on meeting the trials’ internal stopping rules related to potential cerebrovascular events affecting both cell and placebo treated patients. Based on consultation with the FDA, CYTX initiated a thorough safety review consisting of evaluating each adverse event in all of its previous and ongoing cardiovascular trials and conducted additional testing of its product and cellular output. In addition, CYTX implemented several protocol changes to enhance the safety of the trial procedures for patients. CYTX is developing cell therapies based on autologous ADRCs to treat cardiovascular disease and repair soft tissue defects. CYTX's scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive More about Cytori Therapeutics, Inc. (CYTX) at www.cytori.com. ** Disclaimer: The assembled information disseminated by CRWE-PR Finance is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Crown Equity Holdings Inc. (CRWE) will receive 50% of the revenues generated by PolarWeb Media through the use of CRWE’s sites, with PolarWeb Media having the remaining 50%. Entire Disclaimer at www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|